Health AI Central
Peer-Reviewed Publication
JCO Precis Oncol2026;10(8):e2501012.August 1, 2026Journal Article

APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial.

Xiaolei Shi1, Amol C Shetty2, Jarey Wang3, Yang Song2, Philip A Sutera4, Matthew P Deek5, Krishnan R Patel6, Ravi A Madan7, Chad Tang8, James Proudfoot9, Elai Davicioni9, Arif Hussain1, Paul Nguyen10, Christopher Sweeney11, Ella Boytim12,13, Kristine P Lacuna14, Charles J Ryan14,15, Emmanuel S Antonarakis12,13, Phuoc T Tran16, Justin Hwang12,13
1Department of Hematology Oncology, University of Maryland Medical Center, Baltimore, MD.
2Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD.
3Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
4Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY.
5Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
6Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
7Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.
8Department of GU Radiation Oncology, MD Anderson, Houston, TX.
9Veracyte, San Diego, CA.
10Department of Radiation Oncology, Mass General Brigham, Boston, MA.
11South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
12Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
13Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
14Memorial Sloan Kettering Cancer Center, New York, NY.
15The Prostate Cancer Clinical Trials Consortium (PCCTC), New York, NY.
16Department of Radiation Oncology, University of Maryland, Baltimore, MD.
PubMed PMC DOI PDF

Abstract

PURPOSE: A six-gene panel involved in androgen production, uptake, and conversion (APUC-6: HSD3B1, HSD3B2, CYP3A43, CYP11A1, CYP11B1, CYP17A1) may define distinct clinical outcomes in metastatic prostate cancer. This study evaluated the prognostic and predictive value of APUC-6 expression in metastatic castration-sensitive prostate cancer (mCSPC). METHODS: Transcriptomic data from 160 patients in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.